Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $2.08 billion. The enterprise value is $1.57 billion.
Important Dates
The last earnings date was Wednesday, February 25, 2026, after market close.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 66.57 million shares outstanding. The number of shares has increased by 3.15% in one year.
| Current Share Class | 66.57M |
| Shares Outstanding | 66.57M |
| Shares Change (YoY) | +3.15% |
| Shares Change (QoQ) | +0.10% |
| Owned by Insiders (%) | 0.31% |
| Owned by Institutions (%) | 102.90% |
| Float | 60.42M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,348.99 |
| Forward PS | 575.05 |
| PB Ratio | 3.93 |
| P/TBV Ratio | 4.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,014.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.49, with a Debt / Equity ratio of 0.00.
| Current Ratio | 10.49 |
| Quick Ratio | 10.21 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.62% and return on invested capital (ROIC) is -28.06%.
| Return on Equity (ROE) | -40.62% |
| Return on Assets (ROA) | -26.12% |
| Return on Invested Capital (ROIC) | -28.06% |
| Return on Capital Employed (ROCE) | -54.02% |
| Weighted Average Cost of Capital (WACC) | 11.14% |
| Revenue Per Employee | $7,803 |
| Profits Per Employee | -$1.31M |
| Employee Count | 198 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +60.28% in the last 52 weeks. The beta is 1.26, so CLDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.26 |
| 52-Week Price Change | +60.28% |
| 50-Day Moving Average | 26.32 |
| 200-Day Moving Average | 24.57 |
| Relative Strength Index (RSI) | 69.35 |
| Average Volume (20 Days) | 1,019,861 |
Short Selling Information
The latest short interest is 9.18 million, so 13.79% of the outstanding shares have been sold short.
| Short Interest | 9.18M |
| Short Previous Month | 9.24M |
| Short % of Shares Out | 13.79% |
| Short % of Float | 15.20% |
| Short Ratio (days to cover) | 14.43 |
Income Statement
In the last 12 months, CLDX had revenue of $1.55 million and -$258.76 million in losses. Loss per share was -$3.90.
| Revenue | 1.55M |
| Gross Profit | -243.53M |
| Operating Income | -287.37M |
| Pretax Income | -258.76M |
| Net Income | -258.76M |
| EBITDA | -283.99M |
| EBIT | -287.37M |
| Loss Per Share | -$3.90 |
Full Income Statement Balance Sheet
The company has $518.57 million in cash and $2.34 million in debt, with a net cash position of $516.24 million or $7.76 per share.
| Cash & Cash Equivalents | 518.57M |
| Total Debt | 2.34M |
| Net Cash | 516.24M |
| Net Cash Per Share | $7.76 |
| Equity (Book Value) | 527.17M |
| Book Value Per Share | 7.92 |
| Working Capital | 483.67M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$210.95 million and capital expenditures -$2.71 million, giving a free cash flow of -$213.66 million.
| Operating Cash Flow | -210.95M |
| Capital Expenditures | -2.71M |
| Free Cash Flow | -213.66M |
| FCF Per Share | -$3.21 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | -18,599.81% |
| Pretax Margin | -16,748.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.15% |
| Shareholder Yield | -3.15% |
| Earnings Yield | -12.42% |
| FCF Yield | -10.25% |
Analyst Forecast
The average price target for CLDX is $44.50, which is 42.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $44.50 |
| Price Target Difference | 42.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 258.02% |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 11.33 and a Piotroski F-Score of 1.
| Altman Z-Score | 11.33 |
| Piotroski F-Score | 1 |